High-profile studies frequently and repetitively present data on the same patients, particularly in immunotherapy studies

Abstract

There is a pattern of multiple presentations of clinical trials, particularly in oral presentations, at major meetings. In most cases, data presented in subsequent oral presentations related entirely to patients whose data was presented in the previous oral presentation.

Do toxicity patterns vary between programmed death-1 and programmed death ligand-1 inhibitors?

“…The fast pace of oncology trials has led to an increasing reliance on conferences as a means for sponsors to deliver "latebreaking" data. A recent study showed that 31% of clinical trials in lung cancer are presented multiple times in abstract form before final publication (16). As each presentation may focus on a different aspect of the study-for instance, subpopulations or biomarker endpoints-the data included in these presentations are generally not as complete as in the publication.…”